Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: A display device includes: a substrate including a display area and a non-display area surrounding the display area; a light emitting element layer on the display area on the substrate and including a plurality of light emitting elements; and an encapsulating layer on the light emitting element layer and on a portion of the display area and the non-display area; and wherein the substrate comprises an upper surface on which the light emitting element layer is located, a bottom surface opposite to the upper surface, a side surface connected to the upper surface and not parallel to the upper surface, and a first inclined surface connected to the side surface and the bottom surface and not parallel to the side surface and the bottom surface, wherein an edge area of the upper surface of the substrate adjacent to an edge of the substrate, in which a processing trace remains.

Abstract: A display device and method for manufacturing thereof are provided. The display device includes a substrate having a display area and a non-display area, and including an edge, an upper surface having an edge area in which a processing trace remains adjacent to the edge, a bottom surface opposite to the upper surface, a side surface connected to the upper surface and not parallel thereto, and a first inclined surface connected to the side surface and to the bottom surface, a light-emitting element layer above the upper surface of the substrate in the display area, and including light-emitting elements, an encapsulating layer above the light-emitting element layer and corresponding to a portion of the display area and the non-display area, and a protective layer above an outer surface of the substrate, and located on at least one of the bottom surface, the side surface, or the first inclined surface.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A display device includes a timing controlling part generating an image data, a data control signal and a gate control signal; a data driving part generating a data voltage using the image data and the data control signal; a gate driving part generating a gate voltage using the gate control signal; a display panel including a plurality of subpixels and displaying an image using the data voltage and the gate voltage; and a plurality of first MUX switches and a plurality of second MUX switches sequentially transmitting the data voltage to two of a same color among the plurality of subpixels.

Abstract: A display device includes: a substrate comprising an upper surface, a bottom surface facing the upper surface, and a through hole penetrating the upper surface and the bottom surface; and a light emitting element layer on the upper surface of the substrate, wherein the substrate comprises a side surface that meets the upper surface in the through hole, a first surface that meets the bottom surface, a second surface that meets the side surface, and a third surface between the first surface and the second surface, and wherein the first surface and the second surface are spaced apart from each other with the third surface therebetween, and are inclined surfaces.

Abstract: An electronic device includes a display device, which may be fabricated using a described method. The display device includes a glass substrate including a first surface, a second surface opposite the first surface, and a side surface between the first surface and the second surface, an outermost structure on the first surface of the glass substrate and located adjacent to an edge of one side of the glass substrate, and a display area including a plurality of light emitting areas on the first surface of the glass substrate and located farther from the edge of the one side of the glass substrate than the outermost structure is. A minimum distance from the side surface of the glass substrate to the outermost structure is equal to 130 ?m or less.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: The present invention may provide a medical syringe comprising: a cylinder including a stopper protruding inward; and a plunger disposed inside the cylinder so as to move back and forth in a first direction, wherein the plunger includes a plurality of protrusions, and the plurality of protrusions are arranged at intervals along the longitudinal direction of the plunger, and based on the first direction, any one of the stopper or the plurality of protrusions is arranged so as to be selectively overlapped according to the rotation of the plunger.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

Abstract: A method for predicting and/or monitoring the efficacy of a c-Met inhibitor using a biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using a biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.

Abstract: A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.

Abstract: The disclosure is related to a method for distributing data traffic of a wireless local area network (WLAN) in a WLAN access network while providing service continuity and internet protocol (IP) mobility in a heterogeneous network environment. The method may include receiving data traffic generated by user equipment and from a wireless local area network, selecting one of a first data path and a second data path for the received data traffic based on path decision information associated with the received data traffic, and transmitting the data traffic to Internet through the selected data path. The first data path may transmit the data traffic to Internet through a packet data network (PDN) gateway and the second data path may transmit the data traffic to Internet without passing through the PDN gateway.

Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.

Abstract: Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.

Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.